WooGene B&G Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 12, 2022 at 01:50 am
Share
WooGene B&G Co., Ltd reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported negative sales was KRW 0.00001 million. Net loss was KRW 99.47 million compared to net income of KRW 518.78 million a year ago. Basic loss per share from continuing operations was KRW 3 compared to basic earnings per share from continuing operations of KRW 18 a year ago. Diluted loss per share from continuing operations was KRW 3 compared to diluted earnings per share from continuing operations of KRW 18 a year ago. Basic loss per share was KRW 3 compared to basic earnings per share of KRW 18 a year ago.
For the six months, net income was KRW 264.74 million compared to net loss of KRW 547.67 million a year ago. Basic earnings per share from continuing operations was KRW 9 compared to basic loss per share from continuing operations of KRW 19 a year ago. Diluted earnings per share from continuing operations was KRW 9 compared to diluted loss per share from continuing operations of KRW 19 a year ago. Basic earnings per share was KRW 9 compared to basic loss per share of KRW 19 a year ago.
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.
WOOGENE B&G CO., LTD 
